Parataxis Korea, Inc. (KOSDAQ:288330)

South Korea flag South Korea · Delayed Price · Currency is KRW
1,682.00
-68.00 (-3.89%)
At close: Oct 10, 2025
-3.89%
Market Cap147.35B
Revenue (ttm)11.18M
Net Income (ttm)-18.09B
Shares Out87.60M
EPS (ttm)-367.90
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume654,187
Average Volume875,319
Open1,805.00
Previous Close1,750.00
Day's Range1,660.00 - 1,805.00
52-Week Range671.00 - 9,280.00
Beta1.91
RSI32.13
Earnings DateNov 10, 2025

About Parataxis Korea

Parataxis Korea, Inc., a clinical stage biotech company, engages in the development of therapeutics for the treatment of ulcerative colitis, fibrotic diseases, and cancers worldwide. Its products in pipeline includes BBT-401, a Pellino-1 inhibitor, which is in Phase I clinical trial for the treatment of ulcerative colitis; and BBT-877, an autotaxin inhibitor that is in Phase I clinical trial for the treatment of various fibrotic diseases, such as idiopathic pulmonary fibrosis. Bridge Biotherapeutics, Inc. has a research collaboration with Atomw... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2015
Employees 21
Stock Exchange KOSDAQ
Ticker Symbol 288330
Full Company Profile

Financial Performance

In 2024, Parataxis Korea's revenue was 2.18 million, a decrease of -97.82% compared to the previous year's 100.00 million. Losses were -19.76 billion, -53.32% less than in 2023.

Financial Statements

News

There is no news available yet.